📌 X Insight Update[x_fin] (2026/06/29 00:53)

📈 Original Viewpoint Summary

Frontier AI moat compression is the key risk. Chinese models are closing the output-quality gap at ultra-low cost, so the old moat starts fading. The trade shifts to the Phase 2 AI handoff: open-source pressure versus frontier AI, where positioned investors may get paid. 1
AI overflow capacity is being priced as a major 2030 revenue pool. Current estimates frame $CRWV at ~$66.9B revenue w/ 68% EBITDA margins, $NBIS at ~$39.7B revenue w/ 90% EBITDA margins, $IREN at ~$10.9B revenue w/ 74% EBITDA margins, and $WULF at ~$4.3B. The core setup: compute-capacity players become the overflow layer for AI demand. 2
$SPCX / SpaceX can scale into a monster revenue base because the stack is vertically controlled. Revenue is expected to approach ~$100B by 2028, potentially making SpaceX one of the fastest-scaling businesses at that size. The flywheel: control launch capacity, use it to scale Starlink, then compound the infrastructure advantage. 3
$AMZN has a credible path to $1 trillion annual revenue by 2028. The bull case is not just e-commerce. It is simultaneous compounding across commerce, cloud, logistics, ads and AI, turning Amazon into core global infrastructure. 4

Semiconductor PEGs show where growth may already be crowded. The framework is simple: PEG < 1 usually means mispriced growth, while PEG > 2 starts to push into the danger zone. Current stack: $ALAB ~3.6x, $INTC ~2.7x, $LRCX ~2.6x, $KLAC ~2.4x, $AMAT ~2.2x, $ARM ~1.9x, $ASML ~1.7x, $ANET ~1.7x, $LITE ~1.1x. 5
$MU is not a broken chart despite the weekend bear pile-on. Memory sentiment looks heavy, but the setup remains strong as currently constructed. The stock has already quadrupled out of consolidation, so a sharper pullback can happen, but the chart itself is not weak. 6
$NVDA still has not truly backtested support after its breakout. The breakout happened a couple months ago, but the stock has not yet done a proper support check. That keeps the technical setup unresolved rather than exhausted. 7
$AMAT has underappreciated advanced-packaging and DRAM upside. The company is introducing 3 new advanced packaging and DRAM epitaxy systems. DRAM wiring (> $2B cumulative 2020-24) is guided to >3x in 5 yrs, while the capacitor franchise (> $1B) is guided to >4x as 3D ramps. The punchline: higher per-wafer tool intensity is not reflected in consensus mid-teens growth. 8

$TEM has a squeeze-plus-base setup. The ingredients are AI healthcare, Pelosi, and 27% short interest. Technically, the stock is reclaiming key moving averages while building a multi-month base. 9
$AMZN held a key level last week and now faces a pivot week. The setup is about whether last week’s hold turns into follow-through or rejection at the next technical pivot. 10
$UFO is back on watch after a hard flush. The ETF is starting to look interesting after a steep -34% selloff just in the last 20 trading days. Price is nearing 3 notable confluences of support around the $40-$44 area. Related space names: $RKLB $PL $VSAT $LUNR $IRDM $SIRI $ASTS $GSAT. 11
Large-cap laggards may be setting up for a contrarian bounce. Among the 70 stocks with $200B market cap or greater, the worst performers over the last 12 months are $NFLX -43.5%, $ORCL -30.2%, $MSFT -25%, $META -24.2%, and $PLTR -21.7%. The implication: at some point, extreme underperformance starts to matter. 12

$AMLX has faster uptake risk to the upside. Avexitide is already named in EU clinical guidelines despite not being approved there yet. EU physician requests point to faster adoption after approval. Japan adds another under-modeled leg, with 100k annual gastrectomy cases as a second geography. 13

$CROX may be hitting a North America inflection. Management says “at-once” wholesale orders are picking up from partners, the first directional shift in NA after declines every quarter since 2Q24. Combined with Shoe Carnival’s signs of life in canvas/vulcanized, this points to upside versus Street models still baking in declines. 14

Position sizing matters when YTD losers and winners coexist. The practical takeaway: do not casually size up too aggressively, because mixed P/L across the book can mask concentration risk. 15
Nasdaq offers faster growth but higher volatility. Allocation choice is not purely about upside. The tradeoff is simple: more growth, more chop. 16